Emine GÜÇHAN ALANOĞLU, Aslıhan BADUR, Demircan ÖZBALCI

Evaluation of the relationship between sociodemographiccharacteristics, quality of life, depression, drugcompliance and biochemical parameters in patients withthalassemia major in Isparta

Aim: We aimed to evaluate the quality of life and depression levels of BTM patients in our unit, to determine the relationship between each parameter and evaluate the demographic characteristics, laboratory data, and treatment compliance.Materials and Methods: Twenty-seven BTM patients aged 18 years and over were included in the study. Sociodemographic data were collected from the patients with a data form. Laboratory data were obtained from hospital records retrospectively. The patients were asked to respond to the BDI and SF-36 content in which depression was questioned and quality of life was evaluated respectively. The relationship between each parameter was examined.Results: 70,3 % of the patients had minimal-mild and 11,1 % of the patients had severe depression. Depression levels were significantly higher in patients who had a regular job and who had poor compliance to chelation therapy. Physical function and physical role subscales of single patients were significantly higher than married patients. Patients with monthly income had higher quality of life in terms of physical role, mental health, social functioning and pain subscales. The patients without co-morbidity had higher quality of life in terms of physical role, pain and general health subscales. Patients with severe depression had the worst quality of life. The general health perception of patients with minimal depression was higher than those with moderate depression and severe depression.Conclusions: Psychosocial support of patients is important and, therapy should be aimed not only to ensure long life without complications but also improve the quality of life of the patients.

PDF

___

1. Martin A, Thompson AA. Thalassemias. Pediatr Clin North Am 2013;60:1383-91.
2. Williams TN, Weatherall DJ. World distribution, population genetics, and health burden of the hemoglobinopathies. Cold Spring Harb Perspect Med 2012;2 a011692.
3. Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ 2008; 86:480-7.
4. Cappellini M-D, Cohen A, Eleftheriou A, et al. Guidelines for the clinical management of thalassaemia: Thalassaemia International Federation, Nicosia (CY); 2008.
5. Weatherall DJ. The definition and epidemiology of non-transfusion-dependent thalassemia. Blood Rev 2012;26:3-6.
6. Kazanci EG, Bektemur G, Bener S, et al. Preimplantation genetic diagnosis in thalassemia and inclusion of the treatment in the scope of reimbursement evaluation. Health Care 2017;4:135.
7. Tunc B, Cetin H, Gumruk F, Istanbullu B, Yavrucuoglu H, et al. The prevalence and molecular basis of betathalassemia in Isparta province and region. Turk J Pediatr 2002;44:18-20.
8. Origa R. β-Thalassemia. Genetics in Medicine. 2017;19:609.
9. Langhi Jr D, Ubiali EMA, Marques Jr JFC, et al. Guidelines on Beta-thalassemia major-regular blood transfusion therapy: Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular: project guidelines: Associacao Medica Brasileira-2016. Rev Bras Hematol Hemoter 2016;38:341-5.
10. Taher AT, Weatherall DJ, Cappellini MD. Thalassaemia. The Lancet 2018; 391:155-67.
11. Lucarelli G, Isgrò A, Sodani P, et al. Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. Cold Spring Harb Perspect Med 2012;2: a011825.
12. Thalassemia gene therapy nears approval. Nat Biotechnol 2019;37:493.
13. Belhoul KM, Bakir ML, Saned M-S, et al. Serum ferritin levels and endocrinopathy in medically treated patients with β thalassemia major. Ann Hematol 2012;91:1107-14.
14. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis 2010;5:11.
15. Organization WH. Depression and other common mental disorders: global health estimates. World Health Organization; 2017.
16. Beck AT, Steer RA. Internal consistencies of the original and revised Beck Depression Inventory. J Clin Psychol 1984;40:1365-7.
17. Bilge Y, Kulaksizoglu A. A New Scale: Validity and reliability study of the psychological disorders inventory for adolescents. J Int Soc Res 2017;10.
18. Hisli-Sahin N. A study on the validity of the Beck Depression Inventory. Turkish Journal of Psychology 1988;6:118-26.
19. Group W. The World Health Organization quality of life assessment (WHOQOL): position paper from the World Health Organization. Social science & Med 1995;41:1403-9.
20. Edisan Z, Kadıoğlu FG. Health-Related Quality of Life Scales: An Ethical Evaluation. Turkish Clinics J Medical Ethics-Law and History 2011;19:8-15.
21. Framework IC. The MOS 36-item short-form health survey (SF-36). Med Care 1992;30:473-83.
22. Kocyigit H, Aydemir O, Fisek G, et al. Reliability and validity of the Turkish version of Short Form 36 (SF36): Study with a group of patients with rheumatic disease. Medicine and Treatment 1999;12:102.6.
23. Demiral Y, Ergor G, Unal B, et al. Normative data and discriminative properties of short form 36 (SF-36) in Turkish urban population. BMC Public Health 2006;6:247.
24. Beck AT, Ward C, Mendelson M, et al. Beck depression inventory (BDI). Arch Gen Psychiatry 1961;4:561-71.
25. Bush S, Mandel FS, Giardina PJ. Future orientation and life expectations of adolescents and young adults with thalassemia major. Ann N Y Acad Sci 1998;850:361-9.
26. Haghpanah S, Nasirabadi S, Ghaffarpasand F, et al. Quality of life among Iranian patients with betathalassemia major using the SF-36 questionnaire. Sao Paulo Med J 2013;131:166-72.
27. Toret E, Karadas NO, Gokce NO, et al. Quality of Life and Depression in Turkish Patients with β-Thalassemia Major: A Cross-Sectional Study. Hemoglobin 2018;42:326-9.
28. Gan GG, Hue YL, Sathar J. Factors Affecting Quality of Life in Adult Patients with Thalassaemia Major and Intermedia. Ann Acad Med Singap 2016;45:520-3.
29. Safizadeh H, Farahmandinia Z, Nejad SS, et al. Quality of life in patients with thalassemia major and intermedia in kerman-iran (I.R.). Mediterr J Hematol Infect Dis 2012;4: e2012058.
30. Azarkeivan A, Hajibeigi B, Alavian SM, et al. Associates of poor physical and mental health-related quality of life in beta thalassemia major/intermedia. Journal of research in medical sciences: J Res Med Sci 2009;14:349-55.
31. Adib-Hajbaghery M, Ahmadi M, S P. Health Related Quality of Life, Depression, Anxiety and Stress in Patients with Beta-Thalassemia Major. IIran J Ped Hematol Oncol 2015;5:193-205.
32. Sobota A, Yamashita R, Xu Y, et al. Quality of life in thalassemia: a comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms.Am J Hematol 2011;86:92-5.
33. Cakaloz B, Cakaloz I, Polat A, et al. Psychopathology in thalassemia major. Pediatr Int 2009;51:825-8.
34. Aydinok Y, Erermis S, Bukusoglu N, et al. Psychosocial implications of thalassemia major. Pediat Int 2005;47:84-9.
35. Maheri A, Sadeghi R, Shojaeizadeh D, et al. Depression, Anxiety, and Perceived Social Support among Adults with Beta-Thalassemia Major: Cross-Sectional Study. Korean J Fam Med 2018;39:101-7.